TerminatedPhase 1

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery

Lead sponsor

Tracey McLaughlin

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•BMI 25-40

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02550145

Org study ID29010

Timeline

Milestones

Study first posted2015-09-15estimated

Last update posted2024-12-04actual

Study start2014-02actual (month precision)

Primary completion2016-12actual (month precision)

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Men and women ages 18-65

•BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric surgery

Exclusion criteria

•Acute medical illness, such as acute bacterial or viral syndrome, febrile illness, acute abdominal symptoms, orthopedic injury within one week

•History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or uncontrolled hypertension (SBP>160 or DBP>100)

•Pregnancy

•Use of medications that affect glucose metabolism

•Fasting glucose >150 or HbA1c>7.5 on Metformin

•Women of childbearing potential (will have a pregnancy test, in addition use of abstinence for at least one month prior to study or use two types of contraceptives, hormonal implant or Depo Provera)

•Active, uncontrolled psychiatric disease

•Participating in other studies or have received investigational medications within the past month or 5 half-lives of the drug, whichever is longer.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.